THE INVESTOR

▶주메뉴 바로가기

▶본문 바로가기

The Korea Herald

Bio & Medicine

August 28, 2019
Boryung ignites BR2002’s phase 1 clinical trial in US

South Korea’s Boryung Pharmaceutical announced on Aug. 27 it had received approval from the US Food and Drug Administration to start a phase 1 clinical trial of its drug candidate BR2002 The phase 1 clinical trial will be conducted among 90 patients who suffer non-Hodgkin’s lymphoma, a type of c...
August 27, 2019
KRX decides to delist troubled Kolon TissueGene

The Korea Exchange, South Korea’s stock market operator, on Aug. 26 announced its decision to delist troubled Kolon Group ’s US gene therapy-developing unit Kolon TissueGene . In late March, a component of Kolon TissueGene’s gene therapy drug Invossa -- labeled as “a gene-containing chondr...
August 20, 2019
Celltrion establishes Irish unit to expand in European biosimilar market

Celltrion in May established Celltrion Biopharma, its first unit in Ireland, for further expansion in the European biosimilar market, according to industry sources on Aug. 20. At the new unit, the Korean company plans to mainly conduct clinical trials to prove the safety of its biosimilars to loc...
August 12, 2019
OliPass to inject W1.2b for establishing unit in US

South Korean bio company OliPass has decided to inject 1.2 billion won ($988,000) to establish a unit in the US, according to industry sources on Aug 12. The company hopes to further strengthen its partnership with US companies and apply for clinical trials after establishing the new unit. Accord...
August 08, 2019
Yuhan establishes unit in Australia to expand overseas

Korean pharmaceutical company Yuhan announced on Aug. 7 that it has established new unit in Australia to expand its presence further globally. “We established Yuhan ANZ in Australia to focus more on open innovation for discovering new drug candidates and technologies,” the company said in a stat...
August 02, 2019
SillaJen stocks nosedive on Pexa-Vec woes

SillaJen shares bottomed out on Aug. 2 on news that the global phase 3 clinical trials of its signature liver cancer treatment Pexa-Vec are likely to be suspended. The biotech firm trading on South Korea’s tech-heavy bourse Kosdaq, took a 30 percent loss. As a result, the market cap fell to 2.2 ...
August 01, 2019
Celltrion to ignite Remsima SC’s phase 3 clinical trial in US

Celltrion announced on Aug. 1 that it had started a phase 3 clinical trial of its new drug Remsima SC in the US. Remsima SC is a subcutaneous version of Remsima, the Korean company’s biosimilar of Johnson & Johnson’s autoimmune disease therapy Remicade. According to the company, the new pen-type...
July 24, 2019
Samsung Bioepis wins 4th FDA approval for biosimilar

South Korean pharmaceutical firm Samsung Bioepis said on July 24 it has won approval from the US Food and Drug Administration to sell one of its biosimilars in the United States. Hadlima, referencing AbbVie’s blockbuster autoimmune treatment Humira, can be also used for treatment of diseases t...
July 21, 2019
Stocks held by K-pop agency owners plummet

The value of stocks owned by both former and current entertainment agency owners in South Korea dropped nearly 30 percent compared to last year, data showed on July 21, as the industry is struggling to cope with a slew of scandals as well as trade tensions between Korea and Japan, a key market. Ac...
July 21, 2019
How far are we from printing hearts for transplant?

Three-dimensional printing of human organs is not some far-fetched fiction. Active research of the relevant technologies has gained pace around the globe, especially here in South Korea, where the academia, industry and government are paying keen attention to the convergence of medicine, mechanical...
July 21, 2019
Chong Kun Dang, Dong-A ST to launch Nesp biosimilars in Japan in H2

South Korean biopharma firms Chong Kun Dang and Dong-A ST expect to launch their biosimilars in Japan without a headwind, despite escalating trade strife, as their drugs will be represented by Japanese partner firms. The erythropoietin drug Nesp, for which the patent expires in Japan this year...
July 19, 2019
Celltrion establishes JV with Nan Fung Group to enter China

Celltrion announced July 19 that it has established the joint venture Vcell Healthcare in Shanghai with Hong Kong-based conglomerate Nan Fung Group to make a foray into China. Established in 1954, Nan Fung Group’s businesses range from real estate development to life sciences. “We are now one s...
July 19, 2019
HanAll Biopharma invests W5.6b in Roivant Sciences’ subsidiary

HanAll Biopharma , a subsidiary of Daewoong Pharmaceutical, invested 5.6 billion won ($4.76 million) in Switzerland-based biotech startup Roivant Sciences’ subsidiary Immunovant Sciences, according to industry sources on July 19. In return, the Korean company gained a stake in Immunovant Science...
July 18, 2019
Bridge Bio signs licensing deal with Boehringer Ingelheim

Korean biotech firm Bridge Biotherapeutics announced on July 18 that it has signed a contract with German-based pharmaceutical company Boehringer Ingelheim to license out its drug candidate BBT-877. BBT-877 is expected to be developed to treat various fibrotic diseases such as idiopathic pulmonary...
July 17, 2019
Prosecution requests warrant for Samsung BioLogics CEO

The prosecution has requested arrest warrants for Kim Tae-han, CEO of contract drug manufacturer Samsung BioLogics, and two other executives, surnamed Kim and Shim. The Seoul Central District Court will review the request on July 19. Prosecutors had requested arrest warrants in May, but the court ...

1 2 3 4 5 6 7 8 9 10

EDITOR'S PICKS

Herald Corporation |
CEO : Jeon Chang-hyeop |
Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea |
Title : The Investor |
Date of registration : 2016.06.21 |
Date of issue : 2016.06.21

Publisher. Editor : Jeon Chang-hyeop |
Chief Privacy Officer & Juvenile Protection Manager : Ahn Sung-mi |
T +82-2-727-0114

FAMILY SITE GO

Company Registration No. 104-81-06004 |
Mail-Order Business Registration 2016 - Seoul Yongsan - 00590 |
Business info |
Gov’t registration No. Seoul 아04099